600566 Stock Overview
Engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based Chinese traditional medicines, and Chinese medicine health products in China.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Hubei Jumpcan Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥29.55 |
| 52 Week High | CN¥45.18 |
| 52 Week Low | CN¥23.85 |
| Beta | 0.15 |
| 11 Month Change | 20.51% |
| 3 Month Change | -9.88% |
| 1 Year Change | 17.64% |
| 33 Year Change | 81.62% |
| 5 Year Change | 6.14% |
| Change since IPO | 49.17% |
Recent News & Updates
Why Investors Shouldn't Be Surprised By Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) 26% Share Price Plunge
Sep 11
An Intrinsic Calculation For Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) Suggests It's 45% Undervalued
Sep 09Recent updates
Why Investors Shouldn't Be Surprised By Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) 26% Share Price Plunge
Sep 11An Intrinsic Calculation For Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) Suggests It's 45% Undervalued
Sep 09Is Hubei Jumpcan Pharmaceutical (SHSE:600566) A Risky Investment?
Aug 07Is Now The Time To Put Hubei Jumpcan Pharmaceutical (SHSE:600566) On Your Watchlist?
Jul 01Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Prospects Need A Boost To Lift Shares
May 30Hubei Jumpcan Pharmaceutical (SHSE:600566) Ticks All The Boxes When It Comes To Earnings Growth
Mar 17Shareholder Returns
| 600566 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.6% | 1.6% | 2.7% |
| 1Y | 17.6% | 0.7% | 4.6% |
Return vs Industry: 600566 exceeded the CN Pharmaceuticals industry which returned 0.7% over the past year.
Return vs Market: 600566 exceeded the CN Market which returned 4.6% over the past year.
Price Volatility
| 600566 volatility | |
|---|---|
| 600566 Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in CN Market | 11.4% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 600566 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600566's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 5,230 | Fei Cao | www.jumpcan.com |
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based Chinese traditional medicines, and Chinese medicine health products in China. The company offers Chinese and western medicines in the areas of pediatrics, gynecology, pneumology, gastroenterology, and geriatrics; oral and skin care products; and anti-fatigue, anti-aging, antioxidant, and immunity-enhancing Chinese medicine health products. It also develops Chinese and western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis.
Hubei Jumpcan Pharmaceutical Co., Ltd. Fundamentals Summary
| 600566 fundamental statistics | |
|---|---|
| Market cap | CN¥27.24b |
| Earnings (TTM) | CN¥2.82b |
| Revenue (TTM) | CN¥9.06b |
9.7x
P/E Ratio3.0x
P/S RatioIs 600566 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600566 income statement (TTM) | |
|---|---|
| Revenue | CN¥9.06b |
| Cost of Revenue | CN¥1.76b |
| Gross Profit | CN¥7.30b |
| Other Expenses | CN¥4.48b |
| Earnings | CN¥2.82b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 26, 2024
| Earnings per share (EPS) | 3.06 |
| Gross Margin | 80.60% |
| Net Profit Margin | 31.14% |
| Debt/Equity Ratio | 10.0% |
How did 600566 perform over the long term?
See historical performance and comparison